Abstract: Virus infections promoting Chronic Fatigue can be diagnosed by assessing the 2'-5'A/RNase L pathway, including measurement of 2'-5'A oligonucleotide levels in the patient's circulating peripheral leucocytes, and comparing these resuls with those of healthy individuals. Double-stranded RNAs, notably mismatched dsRNAs, when administered in appropriate amounts, increase the 2'-5'A and normalize the antiviral pathway in patients with Chronic Fatigue Syndrome and improve the clinical symptoms.

Abstract: Abnormalities in the circulating immune complexes in a patient's blood, such as observed in patients having inflammatory disorders, viral infections, or simply deranged immune function, are restored to normal or viral immunity conferred by the administration of a matched or mismatched dsRNA.

Abstract: Surfactant-stabilized ternary complexes of dsRNAs in topical pharmaceutical compositions, optionally also including a lymphokine and/or an inhibitor of reverse transcriptase, are applied topically to the affected or exposed area to treat or prevent viral infections, such as herpes virus, and other infectious conditions, particularly venereally transmitted pathogens. Ternary complexes of two strands of complementary RNA plus a compatible surfactant stabilized against temperature-associated enzymatic inactivation are described.

Abstract: Hepatitis viral infections are efficaciously treated with mismatched dsRNAs, notably rI.r(C.sub.11-14,U).sub.n, alone or in combination with one or more ganciclovir, coumermycin A1, dideoxyinosine or its nucleoside analogs.

Abstract: Hepatitis viral infections are efficaciously treated with mismatched dsRNAs, notably rI.multidot.r(C.sub.11-14,.sup.U).sub.n, alone or in combination with one or more of ganciclovir, coumermycin Al, dideoxyinosine or its nucleoside analogs.

Abstract: Abnormalities in the circulating immune complexes in a patient's blood, such as observed in patients having inflammatory disorders, viral infections, or simply deranged immune function, are restored to normal or viral immunity conferred by the administration of a matched or mismatched dsRNA.

Abstract: The use of mismatched dsRNA, e.g., AMPLIGEN.RTM. for the manufacture of compositions for use in the selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phase of the biological continuum of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mismatched double-stranded RNA into various blood products or biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.

Abstract: dsRNA reduces the phenomenon of viral escape and cellular damage attendant thereto. Viral escape is a process by which a virus of intracellular pathogen alters its host range or indirectly alters its susceptibility to antiviral or immunological therapies. Viruses do so by causing specific changes in their genomic/antigenic composition and/or by causing the elaboration of factors which enhance destructiveness of cells and their ability to multiply progeny virus. Animals susceptible to viral infections and pathology secondary to antigenic drift may have damage reduced by exposing them to dsRNA which prevents or substantially minimizes viral escape brought about through these mechanisms of molecular rearrangement and/or elaboration of factors which break down the natural host defenses.

Abstract: Studies of Synergistic combinations of dsRNAs and anti-viral agents in the treatment of viral diseases indicates dsRNA, especially mismatched dsRNA, plays a powerful and versatile role as a core drug in combination therapy for human viral pathogens, notably for ARC and AIDS.

Abstract: The rate of viral dysfunction of subject's immune response in the rate of progression of HIV or like virus from seropositive LAS Pre-ARC ARC frank AIDS is tracked and antiviral therapy based upon dsRNA is initiated and regulated using clinical measurements of the most severe immune deficit as a therapeutic indicator.

Abstract: The use of mismatched dsRNA, e.g. Ampligen for the manufacture of compositions for use in the Selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phases of the biological continuum of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mismatched double-stranded RNA into various blood products of biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.

Abstract: The use of mismatched dsRNA, e.g. Ampligen for the manufacture of compositions for use in the selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Specific treatments for various clinical phases of the biological continuous of AIDS virus-related events ranging from subtle, early immunological lesions to advanced disease are described. Prophylaxis or prevention of AIDS virus related events, such as by introduction of mismatched double-stranded RNA into various blood products or biological fluids to be used in man (e.g., blood transfusion) or around man (e.g., dialysis programs) are also described.